Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

204 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
FDG-PET for management of cervical and ovarian cancer.
Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. Havrilesky LJ, et al. Gynecol Oncol. 2005 Apr;97(1):183-91. doi: 10.1016/j.ygyno.2004.12.007. Gynecol Oncol. 2005. PMID: 15790456
Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.
Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast RC Jr, Berchuck A. Havrilesky LJ, et al. Cancer Res. 1995 Feb 15;55(4):944-8. Cancer Res. 1995. PMID: 7531618
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC Jr, Iglehart JD, Marks JR. Elbendary A, et al. Cell Growth Differ. 1994 Dec;5(12):1301-7. Cell Growth Differ. 1994. PMID: 7696178
Chemotherapy-induced apoptosis in epithelial ovarian cancers.
Havrilesky LJ, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC, Berchuck A. Havrilesky LJ, et al. Obstet Gynecol. 1995 Jun;85(6):1007-10. doi: 10.1016/0029-7844(95)00058-y. Obstet Gynecol. 1995. PMID: 7770245
Pathogenesis of ovarian cancers.
Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr. Berchuck A, et al. J Soc Gynecol Investig. 1994 Jul-Sep;1(3):181-90. doi: 10.1177/107155769400100302. J Soc Gynecol Investig. 1994. PMID: 9419769
Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
Havrilesky LJ, McMahon CP, Lobenhofer EK, Whitaker R, Marks JR, Berchuck A. Havrilesky LJ, et al. J Soc Gynecol Investig. 2001 Mar-Apr;8(2):104-13. J Soc Gynecol Investig. 2001. PMID: 11336882
Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A. Havrilesky LJ, et al. Gynecol Oncol. 2001 Dec;83(3):491-500. doi: 10.1006/gyno.2001.6464. Gynecol Oncol. 2001. PMID: 11733961
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC Jr, Hacker NF. van Haaften-Day C, et al. Among authors: havrilesky lj. Cancer. 2001 Dec 1;92(11):2837-44. doi: 10.1002/1097-0142(20011201)92:11<2837::aid-cncr10093>;2-5. Cancer. 2001. PMID: 11753957
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clarke-Pearson DL, Rodriguez GC, Carney ME. Havrilesky LJ, et al. Gynecol Oncol. 2003 Jan;88(1):51-7. doi: 10.1006/gyno.2002.6859. Gynecol Oncol. 2003. PMID: 12504627 Clinical Trial.
The role of PET scanning in the detection of recurrent cervical cancer.
Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. Havrilesky LJ, et al. Gynecol Oncol. 2003 Jul;90(1):186-90. doi: 10.1016/s0090-8258(03)00256-7. Gynecol Oncol. 2003. PMID: 12821362
204 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page